taletrectinib   Click here for help

GtoPdb Ligand ID: 11198

Synonyms: AB-106 | AB106 | DS-6051b | DS6051b
Compound class: Synthetic organic
Comment: Taletrectinib (DS-6051b) is a next-generation selective ROS1/NTRK inhibitor [2]. It was designed to treat ROS1- or NTRK-rearranged cancers. DS-6051b is able to inhibit the ROS1G2032R mutation that confers resistance to crizotinib, lorlatinib and entrectinib. The compound originates from Daiichi Sankyo and has been licensed to AnHeart.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 77.47
Molecular weight 405.2
XLogP 5.18
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CC(COc1ccc(cc1)c1cnc2n1nc(cc2)NC(c1cccc(c1)F)C)N
Isomeric SMILES CC(COc1ccc(cc1)c1cnc2n1nc(cc2)NC(c1cccc(c1)F)C)N
InChI InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)
No information available.
Summary of Clinical Use Click here for help
Phase 1 results from patients with NSCLC harbouring ROS1 fusions were indicative of favourable safety and efficacy [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02675491 Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Phase 1 Interventional Daiichi Sankyo, Inc.
NCT02279433 A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Phase 1 Interventional AnHeart Therapeutics Inc.
NCT04395677 A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene Phase 2 Interventional AnHeart Therapeutics Inc.